A surgical team at Peking University Shougang Hospital has successfully performed a complex liver resection for hepatocellular carcinoma using the SHURUI® single-port surgical system, marking the first case of its kind in China. The patient, a 63-year-old male with cirrhosis and a centrally located liver tumor, was treated through a single 3–4 cm umbilical incision.
Led by Dr. Jianjun Leng, the team employed preoperative interventional therapy and 3D modeling to shrink the tumor and precisely map vascular anatomy. During surgery, SHURUI® single-port surgical robot delivered exceptional dexterity and visualization, enabling precise dissection around critical blood vessels with minimal blood loss and trauma.
This milestone case showcases the potential of Chinese surgical robotics in hepatobiliary oncology. With its ultra-minimally invasive design, the SHURUI® system expands the boundaries of complex liver surgery—ushering in a new era of precision and patient-centered care in China.
Important Notes
The Single-port Endoscopic Surgical System (SR-ENS-600), developed and produced by Beijing Surgerii Robotics Company Limited, has been approved by the National Medical Products Administration (NMPA) in China for urology and gynecology laparoscopic surgeries. Surgeons who wish to learn the surgical operations of the SHURUI robot should contact Beijing Surgerii Robotics Co., Ltd. to participate in the official training program. Patients who want to participate in the registered clinical trials of the SHURUI robot should contact the official cooperative hospitals of Surgerii and consult with surgeons to determine their suitability for surgery with the SHURUI robot. Both surgeons and patients should carefully understand all information regarding the performance of surgeries by the SHURUI robot and its potential risks.
Beijing Surgerii Robotics Co., Ltd. owns Surgerii®, SHURUI®, and other
trademarks and may not be used without permission.
